The most expensive part of making a biologic drug isn't the molecule. It's the process. Biopharma manufacturers spend billions on single-use bioreactors to avoid costly sterilization between batches. But monitoring what's happening inside those sealed bags still requires a clumsy array of external sensors. InSpek, a Paris-based deeptech founded in 2021, is betting its photonic chip can collapse that entire sensor suite into a single, on-board component.
Jérôme Michon, an École Polytechnique and MIT PhD graduate in integrated optics, co-founded the company with Ivan-Lazar Bundalo. Their proposition is a sensor that uses Raman spectroscopy, a laser-based technique for identifying molecular fingerprints, but shrinks it onto a photonic integrated circuit (PIC). The result, they claim, is a chip capable of real-time, multiparametric monitoring of key bioprocess variables like glucose, lactate, and cell density from inside the bag [CB Insights] [Laser Focus World, 2026].
The hardware wedge in a software-heavy field
InSpek's bet is distinctly physical. While companies like Axio BioPharma coordinate information across disparate manufacturing systems, InSpek is targeting the data source itself. Its differentiation rests on proprietary photonics. The technical challenge is significant: integrating lasers, optical waveguides, and detectors onto a silicon chip that can withstand the sterile, agitated environment of a bioreactor. Michon's academic background and a 2022 X-Grant Silicon Valley prize suggest foundational IP in this integration [École polytechnique, 2026]. The team has grown to 14 full-time staff, including six PhDs in optics, biotech, and AI [PIC Magazine, 2026].
Why Breega and Quantonation wrote the check
In September 2025, InSpek closed a €3.5 million seed round co-led by Breega and Wind, with participation from deep-tech specialist Quantonation [CB Insights, Sep 2025]. This was paired with a €2.5 million grant from the European Innovation Council (EIC) Accelerator. The capital mix is telling:
- Grant de-risking. The non-dilutive EIC funding directly supports the high-cost R&D phase.
- Sector-specific backing. Breega has a track record in European B2B and deeptech, while Quantonation exclusively invests in quantum and advanced physics technologies.
- Total war chest. With total disclosed funding of approximately $7.24 million, InSpek has a substantial budget to move from lab prototypes to pilot deployments [CB Insights].
The path from lab to production floor
The road ahead is defined by milestones common to hard tech. Customer traction is the next, and most critical, gate. No named deployments or partnerships are yet in the public record, placing InSpek firmly in a pre-commercial stage. The sales motion will be long and technical, requiring validation in partner labs and eventual integration into the single-use assemblies made by giants like Cytiva or Sartorius. Regulatory approval for use in Good Manufacturing Practice (GMP) environments will add another layer of time and complexity.
Competitive pressure, while not named in sources, is implicit. Established sensor companies have decades of embedded relationships and offer robust, if discrete, solutions. InSpek's argument is one of integration and superior data. The risk is that being first with a new, complex modality can mean educating the market alone. For biopharma CFOs scrutinizing cost-per-gram, the calculation is simple: can a chip that sees more, inside the bag, materially lift titers and reduce batch failures? InSpek is now funded to prove that the answer isn't just in the data, but in the light.